- Home
- ELUT vs RNXT Comparison
ELUT vs RNXT Comparison
Compare ELUT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELUT | RNXT |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.9M | 37.0M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | ELUT | RNXT |
|---|---|---|
| Price | $0.94 | $0.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $6.00 | ★ $8.25 |
| AVG Volume (30 Days) | 86.4K | ★ 241.1K |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.77 | 20.00 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $12,293,000.00 | $1,123,000.00 |
| Revenue This Year | N/A | $194.66 |
| Revenue Next Year | $10.83 | $279.78 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2511.63 |
| 52 Week Low | $0.50 | $0.70 |
| 52 Week High | $2.60 | $1.45 |
Technical Indicators
Market Signals| Indicator | ELUT | RNXT |
|---|---|---|
| Relative Strength Index (RSI) | 42.45 | 50.64 |
| Support Level | $0.86 | $0.81 |
| Resistance Level | $0.99 | $1.07 |
| Average True Range (ATR) | 0.06 | 0.05 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 13.75 | 49.87 |
Price Performance
Historical ComparisonAbout ELUT Elutia Inc.
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.